Literature DB >> 15203075

Differences in epidemiology, liver disease and treatment response among HCV genotypes.

Stephanos J. Hadziyannis1, John S. Koskinas.   

Abstract

Entities:  

Year:  2004        PMID： 15203075     DOI： 10.1016/j.hepres.2004.02.011

Source DB:  PubMed          Journal:  Hepatol Res        ISSN： 1386-6346            Impact factor:   4.288


× No keyword cloud information.
  12 in total

1.  Interleukin-28B polymorphisms are associated with an early viral response in patients receiving hepatitis C therapy.

Authors:  Rie Osaki; Takashi Nishimura; Takayuki Takeuchi; Hirotsugu Imaeda; Yoshiaki Okumura; Makoto Shioya; Tamio Nakahara; Shigeki Bamba; Shinobu Nakajo; Yoshihide Fujiyama; Akira Andoh
Journal:  Exp Ther Med       Date:  2011-04-07       Impact factor: 2.447

Review 2.  The quasispecies nature and biological implications of the hepatitis C virus.

Authors:  Sarah L Fishman; Andrea D Branch
Journal:  Infect Genet Evol       Date:  2009-08-08       Impact factor: 3.342

3.  Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis.

Authors:  Gaetano Bertino; Annalisa Ardiri; Patrizia Maria Boemi; Giuseppe Stefano Calvagno; Irene Maria Ruggeri; Annalisa Speranza; Maria Milena Santonocito; Dario Ierna; Cosimo Marcello Bruno; Maria Valenti; Roberta Boemi; Simona Naimo; Sergio Neri
Journal:  Eur J Clin Pharmacol       Date:  2010-07-22       Impact factor: 2.953

4.  Evaluation of a new assay in comparison with reverse hybridization and sequencing methods for hepatitis C virus genotyping targeting both 5' noncoding and nonstructural 5b genomic regions.

Authors:  Elisa Martró; Victoria González; Andrew J Buckton; Verónica Saludes; Gema Fernández; Lurdes Matas; Ramón Planas; Vicenç Ausina
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

5.  Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection.

Authors:  Elijah Paintsil; Sergei V Verevochkin; Elena Dukhovlinova; Linda Niccolai; Russell Barbour; Edward White; Olga V Toussova; Louis Alexander; Andrei P Kozlov; Robert Heimer
Journal:  Addiction       Date:  2009-08-27       Impact factor: 6.526

6.  Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.

Authors:  Michele Malaguarnera; Massimo Motta; Marco Vacante; Giulia Malaguarnera; Filippo Caraci; Giuseppe Nunnari; Caterina Gagliano; Carmela Greco; Giuseppe Chisari; Filippo Drago; Gaetano Bertino
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

7.  Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha.

Authors:  Carolina Scagnolari; Pompea Zingariello; Jacopo Vecchiet; Carla Selvaggi; Delia Racciatti; Gloria Taliani; Elisabetta Riva; Eligio Pizzigallo; Guido Antonelli
Journal:  Virol J       Date:  2010-11-12       Impact factor: 4.099

8.  Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.

Authors:  Samir Ali; Vincent Leveque; Sophie Le Pogam; Han Ma; Friederike Philipp; Nicole Inocencio; Mark Smith; Andre Alker; Hyunsoon Kang; Isabel Najera; Klaus Klumpp; Julian Symons; Nick Cammack; Wen-Rong Jiang
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

9.  Hepatitis C virus genotyping using an oligonucleotide microarray based on the NS5B sequence.

Authors:  Dimitry Gryadunov; Florence Nicot; Martine Dubois; Vladimir Mikhailovich; Alexander Zasedatelev; Jacques Izopet
Journal:  J Clin Microbiol       Date:  2010-09-15       Impact factor: 5.948

10.  Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial.

Authors:  Giulia Malaguarnera; Manuela Pennisi; Caterina Gagliano; Marco Vacante; Michele Malaguarnera; Salvatore Salomone; Filippo Drago; Gaetano Bertino; Filippo Caraci; Giuseppe Nunnari; Mariano Malaguarnera
Journal:  Hepat Mon       Date:  2014-05-05       Impact factor: 0.660
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.